相关实验视频
Updated: Jul 11, 2025

08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
Published on: August 31, 2016
15.3K
随着时间的推移,在降低强度的条件下,结果的改善 造血移植:20年的经验
Albert Esquirol1, Irene Garcia Cadenas2, Silvana Novelli2
1Hematology Department, Hospital de La Santa Creu I Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain. aesquirol@santpau.cat.
Annals of hematology
|November 16, 2023
概括
移植后的环胺 (PTCy) 与塔克罗利斯证明了优越的移植对宿主疾病 (GVHD) 控制和降低强度调节 (RIC) 的全源性造血干细胞移植患者的改善生存结果. 这种疗法在RIC环境中为GVHD预防提供了一个有希望的替代方案.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 全基性造血干细胞移植 (HSCT) 是血液恶性瘤的关键治疗方法.
- 减少强度调节 (RIC) 方案越来越多地使用,需要有效的移植对宿主疾病 (GVHD) 预防.
- 存在不同的GVHD预防策略,每个都有不同的疗效和毒性概况.
研究的目的:
- 为了评估不同GVHD预防方案的疗效和结果,在接受RIC全源性HSCT的患者中.
- 为了比较移植后的环胺 (PTCy) - 塔克罗利与其他疗法,包括环素A-甲基酸/酸摩菲提尔和塔克罗利-西罗利.
- 为了确定GVHD的预后因素,非复发性死亡率 (NRM) 和这一患者群体的存活率.
主要方法:
- 在1999年至2020年间,连续484名接受RIC全基性HSCT的患者的回顾性分析.
- 患者接受了三个GVHD预防方案之一:CsA-MTX/MMF,塔克罗利斯-西罗利斯或PTCy-塔克罗利斯.
- 进行了多变量分析,以评估GVHD预防对结果的影响,包括GVHD发病率,NRM,复发,总生存率 (OS) 和无进展生存率 (PFS).
主要成果:
- 中性粒细胞和血小板移植在PTCy-tacrolimus治疗中更快.
- 与其他组相比,PTCy-tacrolimus组显示III-IV级急性GVHD (aGVHD) 和中度至重度慢性GVHD (cGVHD) 的发生率明显较低.
- 在PTCy-tacrolimus组 (68%) 的三年生存期是最高的,相比于tacrolimus-sirolimus (61%) 和CsA-MTX/MMF (49%) 组.
结论:
- GVHD预防是aGVHD和中度至重度cGVHD发展的唯一显著的预后因素.
- 在RIC环境中,PTCy-tacrolimus疗法在GVHD控制和生存方面表现出优异的结果.
- 应考虑PTCy-tacrolimus作为一种首选的GVHD预防策略,用于接受RIC全源性HSCT的患者.
相关概念视频
Bone Marrow Sampling and Transplants
334
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
334
Tissue Transplantation
375
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
375
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K

